PREVENT Toxicology and Pharmacology Testing (PREVENT TOX)

Award Date 9/22/2015
Last Date To Order 9/24/2018
Shared Ceiling $9M
Contract Type
Master IDIQ
Predecessor
Not listed
Successors

The PREVENT Toxicology and Pharmacology Testing (PREVENT TOX) Master IDIQ contract is a specialized federal contract vehicle awarded by the National Cancer Institute (NCI) to support preclinical cancer prevention research. The contract focuses on toxicology and pharmacology testing of potential cancer prevention therapies, providing a structured approach to developing cancer drugs and vaccines from discovery through clinical trials. With a total shared ceiling of $9,000,000, the vehicle enables NCI to contract with multiple research institutions for advanced scientific studies targeting various cancer prevention strategies.

The task orders under this IDIQ primarily involve preclinical research on innovative therapeutic approaches, with recent awards ranging from $1,000 to $2.3 million. Key contractors include the University of Illinois, IIT Research Institute, and SRI International, each performing specialized research on topics such as virus-like particle vaccines, lipid-based drug delivery systems, and targeted molecular inhibitors for conditions like actinic keratosis and skin cancer. The delivery orders consistently support the "Preclinical PREVENT Cancer Program: Toxicology and Pharmacology Testing" major program code, with periods of performance typically spanning two to three years. None of the task orders utilized specific small business set-aside designations, and all were awarded on either firm fixed-price or cost-plus fee pricing structures, reflecting the specialized scientific nature of the research.

Generated 1/16/25, 12:23 AM